EU Clinical Trial 2018-003460-30

A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab plus Olaparib Combination Therapy Compared with Durvalumab Monotherapy as Maintenance Therapy in Patients whose Disease has not Progressed Following Standard of Care Platinum-Based Chemotherapy with Durvalumab in First Line Stage IV Non Small Cell Lung Cancer (ORION)  Mar 6, 2019

Main objective of the trial: To find out the effectiveness of durvalumab combined with olaparib compared to durvalumab alone

Parties

Sponsors